

# Dosimetric evaluation of I-125 seeds for treatment of portal vein tumor thrombosis

Seongmoon Jung<sup>a,b</sup>, Sujeong Lee<sup>c</sup>, Sung-Joon Ye<sup>a,b\*</sup>

<sup>a</sup> Program in Biomedical Radiation Sciences, Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea

<sup>b</sup> Biomedical Research Institute, Seoul National University College of Medicine, Seoul, South Korea

<sup>c</sup> Department of Nuclear Engineering, Kyunghee University, Suwon, South Korea

\*Corresponding author: sye@snu.ac.kr

## 1. Introduction


The portal vein tumor thrombosis (PVTT) is treated with an aid of a metallic stent to reduce portal vein pressure [1]. However, the inserted stents to the patients become narrowing again due to the tumor invasion. By attaching I-125 seeds to the stent, it was reported that the tumor invasion has been successfully controlled [1]. In this study, a dosimetric evaluation of I-125 seeds was performed by using the Monte Carlo code, MCNP6.1 [2]. Our results provide isodose maps for a current configuration of I-125 seeds and would help to develop an optimized one.

## 2. Methods and Results


The model 6711 I-125 brachytherapy seed was modeled [3]. Four columns of I-125 seeds were placed at  $0^\circ$ ,  $90^\circ$ ,  $180^\circ$  and  $270^\circ$  as described in Fig. 1(a). Each column has four I-125 seeds along z-axis (Fig. 1(b)). The diameter of portal vein was assumed to be 12 mm. The material of portal vein and tissue was defined as water.

A cylindrical tmesh tally was used to save the deposited energy at voxels. The voxels were divided by theta ( $\theta$ )  $0^\circ$  to  $360^\circ$  with an increment of  $2^\circ$ , radius ( $r$ ) from 6 mm to 15.5 mm with an increment of 1 mm and z-plane ( $z$ ) from -12.5 mm to 1.25 mm with an increment of 1 mm. Since I-125 seeds were located symmetrically, we defined only two sources of which positions were illustrated in Fig 1(b). We could obtain a total dose distribution by rotating, reversing and summing the results from two sources. All the doses were normalized to the dose at a position  $z=0$ ,  $r=6.5$  mm and  $\theta=1^\circ$ .

Isodose curves for  $z=0$ , 3, 6, 9 and 12 mm were shown in Fig 2. For each z-plane, the maximum dose appeared at the regions close to I-125 seeds (i.e.,  $\theta=0^\circ$ ,  $90^\circ$ ,  $180^\circ$  and  $270^\circ$ ), while cold spots existed at  $\theta=45^\circ$ ,  $135^\circ$ ,  $225^\circ$  and  $315^\circ$ . For  $z=3$  and 6 mm, the maximum dose was about three times higher than that from the normalized point. The dose level at  $z=12$  mm was lower than that from  $z=0$  or 6 mm. Because only four I-125 seed could deposit their energies to the voxels at  $z=12$  mm plane, while eight I-125 seeds could deposit to the voxels at  $z=0$  or 6 mm.



**Fig. 1.** A picture of I-125 seeds (a) [4] and MC model of I-125 seeds. (b) x-y plane and (c) x-z plane are illustrated. A unit of coordinate is mm.



**Fig. 2.** Isodose curves for  $z=0$  to 12 mm. All the doses were normalized to the dose at  $z=0$  mm,  $r=6.5$  mm and  $\theta=1^\circ$ .

### 3. Conclusions

With the current configuration of I-125 seeds for the treatment of PVTT, there were clear hot spots and cold spots, since I-125 seeds were located at  $\theta=0^\circ$ ,  $90^\circ$ ,  $180^\circ$  and  $270^\circ$ . In addition, such hot spots and cold spots were observed along the z-axis. The maximum dose was delivered to  $z=3$  or  $9$  mm at the surface of I-125 seeds. The amount of maximum dose was about 3.4 times higher than the normalized point. By applying our results to the clinical situations, one can change the number of I-125 seeds or its configurations to deliver the prescription dose uniformly and accurately.

### REFERENCES

[1] L Chuan-Xing, H Xu, H Bao-Shan, L Yong, S Pei-Jian, Y Xian-Yi, L Xiao-Ning and L Li-Gong, Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus, *Cancer Biology and Therapy*, Vol. 12, p.865-871, 2011.  
 [2] T Goorley, M James, T Booth, F Brown, J Bull, L J Cox, J Durkee, J Elson, M Fensin, R A Forster, J Hendricks, H G Hughes, R Johns, B Kiedrowski, R Martz, S Mashnik, G McKinney, D Pelowitz, R Prael, J Sweezy, L Waters, T Wilcox, T Zukaitis, Initial Mcnp6 Release Overview, *Nucl Technol*. Vol. 180, p. 298-315, 2012.

[3] J Dolan, Z Li and J F Williamson, Monte Carlo and experimental dosimetry of an  $^{125}\text{I}$  brachytherapy seed, *Med. Phys.* Vol 33(12), p.4675-4984, 2006.  
 [4] CIAE-6711, Chinese Atomic Energy Science Institution, Beijing, China.